China Biologic Products Approved to List on NASDAQ
December 01 2009 - 8:00AM
PR Newswire (US)
TAI'AN, China, Dec. 1 /PRNewswire-Asia-FirstCall/ -- China Biologic
Products, Inc. (OTC:CBPO) (BULLETIN BOARD: CBPO) (NASDAQ:CBPO)
("China Biologic," or the "Company"), one of the leading
plasma-based biopharmaceutical companies in China, today announced
that the Company has received approval to list its common stock on
the NASDAQ Global Market. China Biologic expects its shares to
begin trading on the NASDAQ on Wednesday, December 2, 2009, until
which time its shares will continue to trade on the
Over-the-Counter Bulletin Board. The Company's trading symbol will
remain "CBPO." "We are very proud to have been approved to trade on
the NASDAQ Stock Market and would like to thank our shareholders,
employees, board of directors, and management team for helping us
achieve this significant milestone," said Mr. Chao Ming Zhao, China
Biologic's Chief Executive Officer. "We believe that our ascension
to NASDAQ is a validation of our integrity and our commitment to
sound corporate governance practices. We expect that the trading of
our shares on NASDAQ will improve our visibility within the
investment community, and lead toward increased liquidity and an
expansion of our shareholder base." About China Biologic Products,
Inc. China Biologic Products, Inc. (the "Company"), through its
indirect majority-owned subsidiaries, Shandong Taibang Biological
Products Co. Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd,
and its equity investment in Xi'an Huitian Blood Products Co.,
Ltd., is currently the largest non-state-owned plasma-based
biopharmaceutical company in China. The Company is a fully
integrated biologic products company with plasma collection,
production and manufacturing, research and development, and
commercial operations. The Company's plasma-based biopharmaceutical
products are irreplaceable during medical emergencies, and are used
for the prevention and treatment of various diseases. The Company
sells its products to hospitals and other healthcare facilities in
China. Safe Harbor Statement This release may contain certain
"forward-looking statements" relating to the business of China
Biologic Products, Inc. and its subsidiary companies. All
statements, other than statements of historical fact included
herein are "forward-looking statements," including statements
regarding: the significance of the Company's listing on the NASDAQ
Global Market; the ability of the Company to achieve its commercial
objectives; the business strategy, plans and objectives of the
Company and its subsidiaries; and any other statements of
non-historical information. These forward-looking statements are
often identified by the use of forward-looking terminology such as
"believes," "expects" or similar expressions, and involve known and
unknown risks and uncertainties. Although the Company believes that
the expectations reflected in these forward-looking statements are
reasonable, they do involve assumptions, risks and uncertainties,
and these expectations may prove to be incorrect. Investors should
not place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. The Company's
actual results could differ materially from those anticipated in
these forward-looking statements as a result of a variety of
factors, including those discussed in the Company's periodic
reports that are filed with the Securities and Exchange Commission
and available on its website (http://www.sec.gov/ ). All
forward-looking statements attributable to the Company or persons
acting on its behalf are expressly qualified in their entirety by
these factors. Other than as required under the securities laws,
the Company does not assume a duty to update these forward-looking
statements. For more information, please contact: Company Contact:
Mr. Y. Tristan Kuo Chief Financial Officer China Biologic Products,
Inc. Phone: +86-538-6202206 Email: Web:
http://www.chinabiologic.com/ Investor Relations Contact: CCG
Investor Relations Mr. Athan Dounis, Account Manager Phone:
+1-646-213-1916 Email: Mr. Crocker Coulson, President Phone:
+1-646-213-1915 Email: Web: http://www.ccgirasia.com/ DATASOURCE:
China Biologic Products, Inc. CONTACT: Y. Tristan Kuo, Chief
Financial Officer of China Biologic Products, Inc.,
+86-538-6202206, ; Investor Relations, Athan Dounis, Account
Manager at CCG Investor Relations, +1-646-213-1916, , or Crocker
Coulson, President, +1-646-213-1915, Web site:
http://www.chinabiologic.com/ http://www.ccgirasia.com/
Copyright